Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by complement-mediated intravascular hemolysis, thromboembolic complications and bone marrow failure (BMF), which may range from mild cytopenia to severe aplastic anemia (SAA). 1, 2 Even if the clinical manifestations may change over time, 3 most, if not all PNH patients, have a degree of aplastic anemia (AA) with or without significant hemolysis that may require a treatment according to its severity. While classical hemolytic PNH patients without significant cytopenia other than anemia may respond well to eculizumab, 4, 5 concomitant treatment for patients with associated severe thrombocytopenia or neutropenia is still unknown. Thus, in a small proportion of patients, AA and hemolysis may be present at the same time. To date, to the best of our knowledge, beyond some single case experience, 6, 7 no data are available in the literature concerning the management of this rare condition. Sequential treatment with IST followed by eculizumab seems a logical option, but the majority of PNH patients who develop marrow failure are already on anti-complement treatment or may exhibit clinically meaningful hemolysis, raising the question of a possible concomitant therapy with IST and eculizumab.
Here we retrospectively assessed characteristics and outcomes of patients who have received 'intensive IST' (defined as any lymphocyte-depleting IST regimen based on anti-lymphocyte antibodies, such as horse-or rabbit-antithymocyte globulin, 8 or anti-CD52 monoclonal antibody alemtuzumab 9 ) in combination with eculizumab (concomitantly or sequentially administered), from a cohort of PNH patients seen at our reference centers in France (Saint Louis Hospital of Paris), and in Italy (Federico II University of Naples) between 2007 and 2016.
Among a total of 145 consecutive PNH patients, 9 patients were identified who eventually exhibited aplastic anemia in the context of clinical meaningful hemolysis (AA/PNH syndrome) 3 during their disease course. Patient characteristics are summarized in Table 1 . Median age at AA diagnosis was 29 years. All the patients fulfilled the criteria of SAA 10, 11 due to severe cytopenias involving at least two blood lineages (including transfusion-dependent hyporegenerative anemia not related to complement-mediated hemolysis, i.e. absolute reticulocytes o 60 × 10 9 /L). Since no patient had a HLA-matched family donor for bone marrow transplantation, all the patients received intensive IST according to different institutional regimens. Six out of nine patients were already on eculizumab treatment at time of starting intensive IST (concomitant treatment) whereas three patients received IST in the 3-6 months (median time of 3 months) before the starting of anti-complement therapy (sequential treatment). Five patients had been diagnosed with acquired moderate or severe AA before the appearance of the hemolytic PNH phenotype and had received previous treatments for their BMF (Table 1) .
For all patients already on treatment, eculizumab was not discontinued to minimize the risk of rebound intravascular hemolysis and thrombotic complications. Eculizumab was administered at the standard dose of 900 mg fortnightly in all but one patient, who needed an increased dose (1200 mg) because of pharmacokinetic breakthrough. Antibiotic and antiviral prophylaxis were carried out according local recommendations.
Six SAA patients, including the three undergoing sequential treatment, received standard IST with horse-antithymocyte globulin (h-ATG, ATGAM, 40 mg/kg for 4 consecutive days) combined with cyclosporin A (CsA). The remaining three AA patients received alemtuzumab (3-10-30-30 mg SC in 4 consecutive days) and CsA within the prospective trial NCT00895739; 9 one of these patients a few months later also received a second IST course with rabbit ATG (3.5 mg/kg for 5 consecutive days) and CsA. All the patients completed the scheduled treatment without any side effect, including infusion-related reactions. One of the patients receiving hATG/CSA experienced a reversible hepatic encephalopathy at day +10 of IST in a setting of a previous Budd Chiari syndrome. Lymphocyte depletion was observed in all patients irrespective of sustained therapeutic complement blockade, with lymphocyte count dropping o 100/μL in all cases and lasting for several days (or even months in the case of alemtuzumab). The residual functional activity of complement component 5 (C5) screened using a 50% hemolytic complement (CH50) assay 12 was systematically assessed for five out of nine patients (two receiving concomitant and three sequential treatment). In patients undergoing concomitant IST/eculizumab, no change of CH50 was seen in comparison with basal (pre-IST) levels. Moreover neither change in hemolytic manifestations nor any thromboembolic events were observed with the addition of IST.
All the patients were available for hematological response assessment of underlying AA condition at 6 months. Among the six patients receiving a concomitant treatment we observed one partial response (PR), and two complete responses (CR), whereas the six remaining patients were non-responders (NR). 13 Of NR patients one was rescued with an unrelated BMT obtaining a CR (remaining alive and well 96 months after BMT), while two remained on eculizumab treatment. Patients receiving a sequential therapy were one in PR and two in CR 6 months after introduction of IST. One patient with initial CR eventually relapsed at 3 years showing a myelodysplastic syndrome with chromosome 7 monosomy, and finally died while waiting for an unrelated donor hematopoietic stem cell transplantation. All the other patients are alive at the last follow-up, maintaining their hematological response and carrying on anti-complement therapy. Median follow-up (from day 1 of intensive IST) was 52 months. One additional case of clonal evolution occurred in a patient developing a del(13q) who, nonetheless, remained in CR under a close follow-up (Table 1) . This is the first systematic description of the management of severe BMF in hemolytic PNH patients in the era of anti-complement treatment.
In our experience intensive IST, based on either polyclonal or monoclonal anti-lymphocyte antibodies, can be delivered concomitantly to eculizumab treatment (and vice versa, eculizumab can follow intensive IST), without any unexpected severe side effect or pharmacological interferences. Our study, also suggests the hypothesis that the complement system (and particularly the terminal effector complement, namely the membrane attack complex) is not formally needed for the cytolytic effect of antilymphocytic agents, in agreement with a major role for antibodydependent cellular cytotoxicity or even programmed cell death, rather than complement-dependent cytotoxicity, as previously reported.
14,15 While we have no biological data to illustrate this statement, the clinical responses of some of our patients are in favour of this assumption. Clinical efficacy was in the expected range as in broader AA populations, with an overall response rate of 66% (CR and PR in six out of nine patients). In conclusion, these data highlight that treatment strategies for PNH may be complex, because of possible concomitant presence of distinct clinical presentations. Indeed in case of severe bone marrow failure, intensive immunosuppression should be considered irrespective of concomitant meaningful hemolysis and possible ongoing eculizumab treatment. Overall these findings suggest that in PNH patients with concomitant severe AA who lack a sibling matched donor, immunosuppression may be delivered immediately before eculizumab, or even concomitantly with expected clinical benefit. Letter to the Editor
